Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink

OptiBP recording close up

Today we are happy to announce the closing of a CHF 4.0M($4.3M) round of seed funding led by digital health investor, SeedLink, with additional funding from LabCorp,  Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide.

The funding we’ve received will accelerate Biospectal’s growth trajectory along with the appointments of Silicon Valley-based, interventional cardiologist and influential serial healthcare innovator, Dr. Fred St. Goar, MD, Tim Juergens, General Manager and co-founder of SeedLink, William Hanlon from LabCorp and Kustaa Piha, successful Health Tech Entrepreneur and Investor from Athensmed to the Biospectal Board of Directors.

Full press releases can be found here: